Article
Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
British journal of clinical pharmacology - 1 Jun 1993
Gram L F, Brøsen K
Abstract excerpt
A sparteine test was carried out immediately before (n = 37) and during (n = 33) moclobemide treatment (200 mg twice daily) in 37 patients participating in a controlled clinical trial. The sparteine metabolic ratio (MR) did not correlate with the plasma concentration of moclobemide and/or its oxi...
Topics
- Adult
- Aged
- Benzamides
- Cimetidine
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 Enzyme System
- Debrisoquin
- Female
- Humans
- Male
- Middle Aged
- Mixed Function Oxygenases
- Moclobemide
- Monoamine Oxidase Inhibitors
- Morpholines
- Oxidation-Reduction
- Phenotype
- Polymorphism, Genetic